Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Himalayan Black Raspberry (Rubus ellipticus) is a wild Himalayan fruit dense in anthocyanins—primarily cyanidin-3-O-glucoside and cyanidin-3-rutinoside—along with ellagic acid, gallic acid, and quercetin glycosides that neutralize reactive oxygen species via B-ring catechol hydroxyl electron donation and suppress NF-κB-mediated inflammatory signaling. While no PubMed-indexed clinical trials exist specifically for R. ellipticus as of 2025, ethnobotanical phytochemical profiling confirms bioactive concentrations comparable to the well-studied Rubus occidentalis (black raspberry), whose anthocyanins have demonstrated antiproliferative, cardioprotective, and anti-inflammatory effects in peer-reviewed research.
Reported Benefits (Provisional)
Origin & History
The Himalayan Black Raspberry (Rubus ellipticus) is native to the high-altitude regions of the Himalayas, particularly Nepal, Bhutan, and northern India. This resilient berry thrives in temperate mountain climates. It is highly valued in traditional medicine for its rich concentration of bioactive compounds, contributing to its significant functional nutrition profile.
Research Narrative (Provisional)
As of 2025, no PubMed-indexed clinical trials have been published specifically on Rubus ellipticus (Himalayan Black Raspberry), so no species-specific PMIDs can be cited. Phytochemical profiling studies published in ethnobotanical and food chemistry journals have confirmed that R. ellipticus berries contain cyanidin-3-O-glucoside, cyanidin-3-rutinoside, ellagic acid, gallic acid, and quercetin-3-rutinoside at concentrations comparable to other wild Rubus species. The closely related Rubus occidentalis (North American black raspberry) has been extensively studied, with clinical and preclinical data demonstrating that its anthocyanins reduce markers of oxidative stress, inhibit NF-κB activation, and exert antiproliferative effects in colorectal and oral cancer models. Researchers recommend that dedicated human clinical trials on R. ellipticus are warranted to confirm the translational relevance of these mechanistic findings to the Himalayan species.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Phytochemicals: Rich in anthocyanins (e.g., cyanidin-3-glucoside, delphinidin), polyphenols (e.g., ellagic acid, quercetin, gallic acid), flavonoids (e.g., kaempferol, rutin), and ellagitannins, providing potent antioxidant activity. - Vitamins: Contains Vitamins C and K, supporting immune function and bone health. - Minerals: Manganese and potassium, essential for metabolic processes and electrolyte balance. - Dietary Fiber: High in prebiotic fiber, promoting gut microbiome balance and digestive health.
Reported Mechanism (Provisional)
The primary bioactive anthocyanins—cyanidin-3-O-glucoside (C3G) and cyanidin-3-rutinoside—donate electrons from their B-ring catechol hydroxyl groups in the flavylium cation form, directly scavenging superoxide anion (O₂⁻), hydroxyl radicals (·OH), and peroxyl radicals, thereby reducing lipid peroxidation and protein carbonylation. Ellagic acid and gallic acid synergistically inhibit the NF-κB signaling cascade by blocking IκB kinase (IKK) phosphorylation, which suppresses transcription of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. Quercetin glycosides (particularly quercetin-3-rutinoside) inhibit cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) expression, further attenuating inflammatory mediator production. Additionally, the undigested polyphenol fraction and prebiotic dietary fiber reach the colon where they are metabolized by Bifidobacterium and Lactobacillus species, producing short-chain fatty acids (SCFAs) such as butyrate that reinforce intestinal barrier integrity and modulate systemic immune tone.
Clinical Narrative (Provisional)
Current evidence consists primarily of preliminary in vitro and animal studies with limited human observational data. In vitro research demonstrates inhibition of CD4+ and CD8+ T lymphocyte proliferation and MDSC expansion, though specific sample sizes and quantified outcomes are not well-documented in available literature. Animal studies suggest cardiovascular and neuroprotective benefits, but robust randomized controlled trials with adequate sample sizes are lacking. The evidence strength remains preliminary and requires further clinical investigation to establish therapeutic efficacy.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.